The Affordable Care Act (ACA) includes a mandate requiring most private health insurers to cover routine patient care costs for cancer clinical trial participation; however, the impact of this provision on cancer centers' efforts to accrue patients to clinical trials has not been well described. METHODS: First, members of cancer research centers and community-based institutions (n 5 252) were surveyed to assess the status of insurance denials, and then, a focused survey (n 5 77) collected denial details. Univariate and multivariate analyses were used to examine associations between the receipt of denials and site characteristics. RESULTS: Overall, 62.7% of the initial survey respondents reported at least 1 insurance denial during 2014. Sites using a precertification process were 3.04 times more likely to experience denials (95% confidence interval, 1.55-5.99; P .001), and similar rates of denials were reported from sites located in states with preexisting clinical trial coverage laws versus states without them (82.3% vs 85.1%; v 2 5 50.7; P .001). Among the focused survey sites, academic centers reported denials more often than community sites (71.4% vs 46.4%). The failure of plans to cover trial participation was cited as the most common reason provided for denials (n 5 33 [80.5%]), with nearly 80% of sites (n 5 61) not receiving a coverage response from the insurer within 72 hours. CONCLUSIONS: Despite the ACA's mandate for most insurers to cover routine care costs for cancer clinical trial participation, denials and delays continue. Denials may continue because some insurers remain exempt from the law, or they may signal an implementation failure. Delays in coverage may affect patient participation in trials. Additional efforts to eliminate this barrier will be needed to achieve federal initiatives to double the pace of cancer research over the next 5 years. Future work should assess the law's effectiveness at the patient level to inform these efforts. Cancer 2017;123:2893-900.
INTRODUCTION
The Affordable Care Act (ACA) not only significantly increased the number of Americans with health insurance, but is the first national mandate to require most private health plans and insurers to provide coverage of routine patient care costs for items and services furnished in connection with participation in a clinical trial. 1 This component of the legislation is important because insurance denial of routine care costs for trial participation and the length of time to receive a response about coverage from the insurer have both been identified as formidable barriers to adult cancer clinical trial enrollment. [2] [3] [4] [5] [6] [7] [8] [9] [10] An examination of this self-implementing statute 11 has yet to be reported. Research on the effectiveness of state and federal policies enacted before the ACA and aimed at eliminating the insurance denial barrier yielded variable results regarding the impact on cancer clinical trial participation. 4, 7, [12] [13] [14] [15] [16] Before the ACA, federal regulations required trial coverage for Medicare beneficiaries. State statutes were in place to cover patients under other plans but varied in the types of trials, beneficiaries, and payers affected; this created inconsistency in coverage. 17 For example, Medicaid coverage rules are set by each state, and not every state requires trial coverage for Medicaid plans. 18 Even now under the ACA, some plans are exempt from the trial coverage mandate. Grandfathered plans are insurance plans that existed on or before the date of ACA implementation (March 23, 2010) and have not made significant coverage changes since that date. These plans are not required to meet the ACA's clinical trial provision as long as they maintain their pre-ACA set of benefits. 19 Health insurance plans federally regulated under the Employee Retirement Income Security Act of 1974 can qualify as grandfathered health plans and can be exempt from the coverage requirement. 20 The degree to which these exempt plans affect trial participation is unknown. 21 The current national initiative 22 to accelerate cancer research to "end cancer as we know it" by doubling the pace of cancer research over the next 5 years will likely involve conducting more clinical trials and enrolling more patients in trials. The success of this Cancer Moonshot may be affected if insurance denials and delays for trial participation continue.
The goal of this study was to assess early implementation of the ACA clinical trial mandate for cancer patients. Specifically, we wanted to understand whether insurance denials persist and, if so, to evaluate the reasons that insurers use to justify denying coverage and to identify specific research-site characteristics associated with denials.
MATERIALS AND METHODS

Study Sample
We surveyed diverse organizations conducting cancer clinical trials about their experience with insurancecoverage denials during the 2014 calendar year, the first year of the ACA trial mandate. The sampling frame consisted of academic and community-based research sites conducting cancer clinical trials and affiliated with the American Association of Cancer Institutes/Clinical Research Initiative, American Society of Clinical Oncology/Research Community Forum, Midwest Cancer Alliance, and Oncology Nursing Society/Clinical Trials Nurses Special Interest Group. Approximately 550 nonduplicate, distinct research sites were represented by these 4 organizational membership lists in the initial survey, with a subset of these sites represented in the focused survey. Survey participants were incentivized with opportunities to receive a tablet computer and gift cards. The institutional review board at the University of KansasLawrence exempted this study from human subjects review.
Survey Design
The survey questions were drafted with an iterative design process with a review by content experts. The survey focused on interventional treatment trials to narrow the scope of the project to include only cancer-treatment (vs prevention or detection) trials. Pretesting of the survey questions was performed with 4 representatives from the sampling frame. On the basis of feedback and a review of the data, the survey was divided into 2 instruments with multiple-choice and open-ended responses to improve clarity. The survey administration followed the recommendations of Dillman et al 23 for Internet-based surveys, and both surveys were administered through SurveyMonkey. 24 
Data Collection
Initial survey
To rapidly ascertain whether insurance denials continued after the ACA's directive (effective January 1, 2014), the initial survey was launched on April 6, 2015, and captured responses over a 5-week period. E-mails with the survey link were sent by the respective organizations to 1412 individuals associated with at least 1 of the participating organizations. The initial 5-question survey asked respondents to report their experience with receiving denials from insurance companies for patients seeking trial participation along with basic site characteristics. Respondents were also asked to identify an organizational representative who could provide more thorough information about their oncology clinical trial program, including the process for determining insurance coverage for potential trial participants. This brief questionnaire provided a timely, broad assessment of the status of clinical trial insurance denials.
Focused survey
The follow-up focused survey was conducted from May to July 2015 and was sent to key informants identified from the initial survey as well as interested individuals identified during the July 2015 meeting of the American Association of Cancer Institutes/Clinical Research Initiative. This survey included 31 items pertaining to additional detailed experiences with insurers related to coverage for trial participation as well as a more comprehensive set of organizational characteristics.
Measures
The response from insurers concerning the coverage of routine care costs for trial participation (no vs yes) was the main outcome variable. Having confirmed that sites were experiencing denials, we sought to identify research-site characteristics associated with denials and to evaluate the reasons that sites recorded as the insurers' explanations for denying coverage. We collected the reasons that sites were given by the insurers for denying coverage (nonmutually exclusive categories). Delays in the initiation of treatment for cancer are known to significantly affect morbidity and mortality, so we evaluated the length of time that sites Original Article reported it took to receive an insurer's response regarding trial coverage (in days).
Site characteristics included the type of organization (academic or community), any National Cancer Institute designation, annual clinical trial enrollment, and use of a precertification process. Precertification refers to obtaining approval from a patient's insurer or health plan before certain tests are ordered or treatments are administered to confirm insurance payment and to inform the patient of any health care costs for which the patient may be responsible. Nearly 40 states and the District of Columbia enacted laws or cooperative agreements requiring insurers to cover routine care costs of cancer clinical trials before the ACA; thus, we included a variable to control for previously existing state laws.
To minimize bias, duplicate entries from the same institution were deleted after they had been evaluated by 2 of the researchers; an algorithm was used to identify identical responses by institutional name, city, and zip code. If the institution's name was identical but the city was different, both entries were retained to reflect multiple locations. If the name and the city were identical, the entry reporting the highest enrollment was kept, with the expectation that with higher enrollment, sites would have greater experience with interacting with insurers. Surveys returned with missing responses for the variables under evaluation were excluded from analysis.
Statistical Analysis
We summarized the reported experiences with insurance denials by numbers and percentages of responses. Univariate statistical analysis was used to assess whether receiving an insurance denial occurred with the use of a precertification process and separately with the presence of previous trial coverage legislation. Multivariate logistic regression was used to measure the relation between experiencing denials and performing precertification; we controlled for the number of enrollments and the presence of previous state law. We used additional univariate analysis to evaluate potential associations between the variables in the focused survey. Relations between variables were considered statistically significant at the P < .05 level. Analyses were conducted with Stata statistical software (version 14.0). 25 
RESULTS
Denial Experience: Initial Survey
The initial survey sample included 1412 individuals and yielded 309 responses (a 22% response rate). Following the a priori algorithm, we excluded 57 responses (46 duplicates and 11 incomplete responses) and thus analyzed 252 unique site responses. The respondents represented 48 states and the District of Columbia. Most respondents (n 5 158 [62.7%]) reported experiencing at least 1 insurance denial at their site during calendar year 2014. Sites with coverage legislation before the ACA experienced rates of denials similar to those of sites in states without coverage legislation (82.3% vs 85.1%; v 2 5 50.7; P .001). Sites performing precertification were more likely than those not performing precertification to report experiencing denials (69.3% vs 41.7%; v 2 5 14.9; P .001). After we had controlled for the institution type, presence of state laws, and enrollment volume, sites using a precertification process were still significantly more likely to experience denials than sites without a precertification process (odds ratio, 3.04; 95% confidence interval, 1.55-5.99).
Research-Site Characteristics: Focused Survey
From the 204 academic and community-based sites identified for the detailed assessment, 97 responses were Table 1 . In this smaller subset analysis, although academic medical centers reported experiencing a denial more often than community sites (71.4% vs 46.4%) and sites using a precertification process were more likely to report denials than sites without a process (58.7% vs 28.6%), neither relation showed statistical significance. None of the evaluated site characteristics showed significance.
Reported Insurer Responses
The survey allowed sites to report multiple reasons for insurance denials, as shown in Figure 1 . Of the sites experiencing denials (n 5 41), most (n 5 33 [80.5%]) reported being informed that the patient's plan did not cover trial participation. More than one-third of the sites reported that the plan was grandfathered under the ACA and, therefore, not required to cover clinical trials (n 5 16 [39.0%]). A similar number of sites (n 5 14 [34.2%]) reported having a Medicare Advantage (MA) plan as a denial reason. Statistically significant reasons (red bars in Fig. 1 ) for denials at academic sites versus community sites included mention of the trial phase not being covered (P 5 .038), without the specific phase identified, and the research site being excluded from the plan's provider network (P 5 .009). Other reported reasons for denials included having a Medicaid plan, using tests and medications not considered standard of care by the insurer, and having international health insurance. Only 20.8% of the sites (n 5 16) reported receiving a decision from the insurer within 3 days of the initial request (Fig. 2) .
DISCUSSION
Participation in clinical trials as part of cancer treatment is recommended by many medical and scientific professional organizations,
26-28 and insurance denial for participation has been identified as an enrollment barrier. 2, 5, 7, 9, 14, 15, 29, 30 This study was conducted in 2015 to identify persistent challenges of the ACA trial mandate within its first year. The results of this national survey drawing from a wide pool of academic and communitybased research programs present evidence that denials continued after the enactment of the ACA.
Sites reported a number of reasons that insurers provided to justify coverage denial (Fig. 1) . The most frequent denial reason that sites reported receiving was that the insurer claimed the plan did not cover trial participation (n 5 33). The site being out of the insurers' provider network (n 5 16) and the plan being grandfathered (n 5 16) were the second most frequently reported reasons for denials. This finding is consistent with the case study of grandfathered plans remaining a barrier to enrollment reported by Jain et al. 9 A 2015 Kaiser Family Foundation survey reported that an average of 25% of covered workers were enrolled in grandfathered plans, with the percentage as high as 42% for individuals employed in firms with 25 to 49 employees. 31 This suggests that a significant segment of the population may be without trial coverage. Plans are expected to lose their grandfathered status over time. Currently, there is no publically available list of grandfathered plans. Thus, to assess whether a plan is truly exempt from this mandate, research centers must take additional steps to confirm an insurer's grandfathered status. Although this step may cause an added burden, it may ultimately result in trial coverage being affirmed.
The fourth reason reported for denials was a patient's participation in an MA plan (n 5 14). These patients are protected under the clinical trial policy national coverage determination issued by the Centers for Medicare & Medicaid Services in 2000 32, 33 through traditional Medicare. The MA plan is required to compensate the enrollee only for the difference in out-of-pocket costs between traditional Medicare and their MA plan. 34 As such, MA plans routinely issue coverage denials because they are not required to cover clinical trials, but they often do not clarify that the MA enrollee still has coverage under traditional Medicare. If MA enrollees and providers do not understand that they have protections under traditional Medicare and the MA plan does not provide information, MA participants may be left out of trial participation entirely.
A few sites reported that potential participants were excluded from trials because of Medicaid denials (n 5 4), which may be a legitimate exclusion. The ACA clinical trial mandate does not apply to Medicaid plans, and federal Medicaid requirements do not include clinical trial coverage. Therefore, it is left to the individual states to determine Medicaid clinical trial coverage benefits. 35 Although 10 states and the District of Columbia have rules that ensure coverage for Medicaid beneficiaries, 17 the majority of states do not clearly require coverage, and Medicaid beneficiaries may not be able to participate because of the lack of coverage. The generalizability of clinical trial results is often scrutinized because of the underrepresentation of certain subgroups of the overall cancer population, including racial and ethnic minorities and the elderly. Removing the insurance barrier to Medicaid beneficiaries may help to make trial participants more representative of all cancer patients.
Academic sites were more likely to indicate a denial due to the phase of the trial and the site being excluded from the plan's network. Historically, early-phase (especially phase 1) clinical trials have been conducted by academic sites more often than community sites. This is due to the ability of academic sites to provide infrastructure to support the increased demands of early-phase trial conduct, including increased personnel, specialized equipment, and adequate treatment space. 36 In addition, changes in the health care environment have resulted in increasingly narrow networks: many insurance plans limit the providers and sites available to enrollees, with the narrowest networks typically excluding academic centers. 37 There may be 2 possible explanations for the association between conducting precertification and experiencing denials. First, because claim forms may not indicate that services were performed within the context of a trial, an insurer may not be aware that a patient is enrolled in a clinical trial if a site does not conduct precertification. Although the Medicare program has had a clinical trial policy in place since 2000, mandatory reporting of the clinical trial number and specification of routine care and research-related procedures was not mandatory until January 2014. 38 Alternatively, the precertification process itself may be engendering higher levels of scrutiny from the insurers than what might otherwise be provided. When alerted to a clinical trial, insurers may employ greater scrutiny of individual coverage elements in addition to determining whether the specific policy provides coverage. There was not a significant association between the use of precertification and the type of research site, and in fact, more of the community sites (89.8%) than academic centers (76.5%) reported using a precertification process (data not shown).
Since this survey was conducted, the Departments of Labor, Health and Human Services, and the Treasury issued a document (dated April 20, 2016) to provide some clarification for the ACA clinical trial policy. 39 Though beneficial, the document does not fully address the amount or type of documentation that insurers can require to approve trial participation, nor does it limit the duration of time to render a determination of coverage. Consequently, implementation ambiguity may remain, and patients and their providers may be left to seek alternative treatment options because of treatment-initiation delays.
The lack of a timely response from an insurer regarding trial coverage may have profound effects on the patient. Aside from the anxiety of coming to terms with a cancer diagnosis or disease progression, the patient may be required to remain in the geographic area in which the planned treatment is to take place, and this could mean a lengthier hospital or hotel stay. In some cases such as acute leukemias, the need for treatment is immediate; thus, the possibility of being treated in a trial must be abandoned, and an alternative therapy must be considered. A shortened, standard review time for approval, if required at all, could be beneficial.
Implications
Delays and denials from insurance companies related to clinical trial coverage prolong and further complicate the process of enrolling patients into clinical trials. Described as a structural barrier to trial participation within the framework recently presented by Unger et al, 40 a lack of insurance coverage, either real or perceived, can deter both patients and providers from considering a trial. Although it is just 1 step in the complex enrollment process, it is conceivable that with the simple removal of the uncertainty of trial coverage for everyone, patients, providers, and the drug development community at large could focus on addressing the more complicated barriers affecting trial enrollment. With fewer obstacles to overcome, the number of trials that fail to complete or are suspended because of slow or inadequate enrollment will decrease, and knowledge of safe and effective therapies will grow. Ultimately, patients will benefit, and providers and payers will have evidence to recommend and cover new therapies.
Cancer centers must have effective and timely communication with the insurers to confirm that patients have trial participation coverage and to establish a process that allows immediate escalation when coverage is declined. However, they must also engage insurers in addressing this problem because it cannot be solved by cancer centers alone. Our study asked cancer centers to describe the reasons that insurers reported for denying trial coverage, but it did not query insurers directly. It is presumed that insurers issue coverage denials because of perceived increased costs, despite evidence indicating the incremental cost of treatment on trial versus off trial is negligible [41] [42] [43] and the potential short-term savings from not paying for trial patients' investigational therapies. However, little research has been conducted on insurers' motivations.
The degree to which denials are intentional or the result of outmoded operations inconsistent with policy is not known. Intervention strategies with insurers might be more effectively broached if potential miscommunications identified here were the focus of initial efforts: working with MA providers to clarify trial coverage policies and publicly reporting plans' grandfathered status. Longterm strategies might enable insurers to consider the return on their investment in clinical trials as opportunities to replace therapies of inferior value with more effective therapies that may reduce treatment intensity with fewer adverse effects. These efforts could be balanced by continued education to increase awareness among plan purchasers and their beneficiaries of the value of supporting the Cancer Moonshot through trial coverage.
Limitations
Several factors should be considered when one is reviewing these results. First, survey respondents may not reflect the experiences of all research organizations. Birken et al 44 emphasized "the need for a comprehensive list of programs that provide cancer treatment as a resource for researchers who study cancer programs." Without an exhaustive sampling frame that includes all organizations/ providers conducting cancer clinical trials, it is difficult to know how reflective respondents are of all research sites. We addressed this by partnering with a variety of professional organizations active in cancer clinical research at diverse research sites. Second, there may be other research-site characteristics that are associated with clinical trial participation that we were unable to measure, such as patient characteristics, provider attitudes toward clinical trials, and trial complexities. 10, [45] [46] [47] In conclusion, this is the first empirical evaluation of the ACA clinical trial mandate. Our results showed persistence of insurance denials for routine costs associated with clinical trials despite this statutory requirement. In our sample, there was a statistically significant difference between reported denials from academic centers and community sites, with numerous denial reasons reported. Taken collectively, the results of this study demonstrate that insurance denials and delays continue to be formidable barriers to both the research and clinical communities in achieving adequate and timely trial enrollment and thus negatively affect the pace of cancer research. There remains the need for further promotion of insurance coverage and an evaluation of the challenges to implementation of this ACA requirement to inform future action to eliminate this enrollment barrier.
